Pharmaceutical Repackaging – A Growth Market in Patient-centric Healthcare
Pharmaceutical repackaging has become a growth market amidst
an increasingly patient-centric healthcare market for a number of reasons: to fit
with the dosage and formulation needs of different patient groups; to reduce treatment
administration errors associated with doses in liquid form at the point of
patient care; to eliminate residual quantities of addictive prescription
medicines; to improve patient compliance by resizing or reformulating in more
convenient dosages; or for improved convenience to the healthcare practitioner by
changing the method of administering to a patient; and lastly but certainly not
the least is the importance of reducing
cost. In some cases, however, the market opportunities for repackaging are less
clear. By conducting interviews and online surveys with the 4Ps (Patients,
Providers – Drs., nurses etc., Payors – health insurance providers and Pharma –
supplier of primary packaging material) of the healthcare sector, i3 Consult
can achieve a 360o perspective on the pain points and opportunities
for establishing a USP (unique selling point) in your pharma repackaging space.
i3 Consult can also solicit primary and secondary research to
establish a predictive value of plastic bottles being used as packaging for your
oral drugs distributed in bulk and prescription dose volumes to retail and mail
order pharmacies and conduct a competitive analysis of other innovative
packaging methods.
Although blister packaging is likely to maintain favorable
growth based on its adaptability to unit-dose formats with expanded-label
content, high visibility, and built-in track-and-trace features, there are
other innovations which need evaluation to optimize the client’s market
position and marketing mix (MM). For example, Dupont’s Surlyn® offering high
patient visibility, significant weight and volume reduction as well as related
pharmaceutical pouches are forecasted to expand in the pharma repackaging space
and hence a feasibility study may need to be conducted around these
opportunities.
I3 Consult as part of its competitive landscape analysis can establish
what product repackaging elements have become the essential part of the drug
delivery system as well as the core elements of the MM.
In today’s patient centric healthcare market[1],
Providers have found in-house dispensing as a new revenue stream as well as
achieving greater compliance and outcomes. i3 Consult will establish for the
client an optimal market position with in-house dispenser partners (selected
Providers) and Pharma vendors. After conducting an in-depth value chain (figure
1) and competitive landscape (figure 2) analyses, a comprehensive road map will
establish both the optimal MM and USP impacting on value-added service for
Patients which in turn will distinguish the service and product among the
client’s competition.
Figure 1: Value Chain Analysis
Figure 2: Porter’s Five Forces Analysis
Comments
Post a Comment